Dry Eye Syndrome – India Drug Forecast and Market Analysis to 2024

Date: 2016-08

Dry Eye Syndrome – India Drug Forecast and Market Analysis to 2024


Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis’ recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.

Diagnosis and treatment rates are expected to increase slightly for all severities of DES in India over the course of the forecast period. This rise in treatment is mainly due to improving disease awareness among both physicians and patients, which will be the main source of growth in this otherwise stagnant market. Allergan’s Restasis is the only approved prescription DES drug in the Indian dry eye market, and was the leading drug (ahead of artificial tears products) in 2014.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


– Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in India from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting India DES market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for DES.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in India.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample